IMPROVE Risk Score for Venous Thromboembolism (VTE)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Very Low Risk0–0
  • Low Risk1–1
  • Moderate Risk2–2
  • Moderate-High Risk3–3
Direct Clinical Answer

The IMPROVE Risk Score for Venous Thromboembolism (VTE) calculates predicting 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. Key inputs include previous vte. Scores guide initiating targeted anticoagulation therapy, platelet monitoring, or hematology specialist referral. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.

Clinical Indication

The IMPROVE Risk Score for Venous Thromboembolism (VTE) is indicated for bedside clinical practice to support Predicts 3-month risk of acute venous thromboembolism (VTE) in hospitalized medical patients. The IMPROVE (International Medical Prevention Registry on Venous Thromboembolism) Predictive score was developed to assess VTE risk in hospitalized medical patients and help identify patients who may not require pharmacological thromboprophylaxis. This validated clinical prediction tool uses 7 clinical variables present at admission or during hospitalization to stratify patients into risk categories. Patients with scores <2 (representing <1% 3-month VTE risk) may not warrant pharmacologic thromboprophylaxis, while those with scores ≥2 should receive prophylaxis. The score is particularly valuable for identifying low-risk medical patients who can safely avoid anticoagulation.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with coagulopathy, thrombocytopenia, venous thromboembolism (DVT/PE), or hematologic neoplasms. Clinical application is indicated across Hematology-oncology services, bone marrow transplant units, anticoagulation clinics, and acute medical wards.

Limitations & Contraindications

Severe thrombocytopenia with concomitant microvascular thrombosis (TTP, HIT, DIC) represents a medical emergency requiring rapid intervention.

Clinical Pearls & Action Plan

Detailed history of heparin exposure, platelet count kinetics, and comprehensive coagulation profiles are vital in consumptive coagulopathies.

Formula & Variables:

Score = Previous VTE (3) + Known thrombophilia (2) + Current lower-limb paralysis (2) + Current cancer (2) + Immobilized ≥7 days (1) + ICU/CCU stay (1) + Age >60 years (1)

Input Parameters

NameTypeRequiredDescription
previous_vtestringYesHistory of previous venous thromboembolism (deep vein thrombosis or pulmonary embolism). Previous VTE is the strongest risk factor, carrying the highest point value due to increased likelihood of recurrence
known_thrombophiliastringYesKnown thrombophilia or hereditary thrombotic disorder (Factor V Leiden, prothrombin gene mutation, antithrombin deficiency, protein C or S deficiency, antiphospholipid syndrome). Thrombophilic disorders increase VTE risk through various mechanisms affecting coagulation
current_lower_limb_paralysisstringYesCurrent lower-limb paralysis or paresis affecting mobility. Paralysis increases VTE risk through venous stasis and reduced muscle pump function in affected limbs
current_cancerstringYesCurrent active cancer diagnosis. Cancer increases VTE risk through multiple mechanisms including tumor-related procoagulant factors, chemotherapy effects, and reduced mobility
immobilized_7_daysstringYesImmobilized ≥7 days immediately prior to and during hospital admission. Prolonged immobilization increases VTE risk through venous stasis and activation of coagulation pathways
icu_ccu_staystringYesCurrent stay in intensive care unit (ICU) or coronary care unit (CCU). Critical care setting indicates severe illness with increased VTE risk from immobility, procedures, and systemic inflammation
age_over_60stringYesAge greater than 60 years. Advanced age increases VTE risk through age-related changes in coagulation factors, decreased mobility, and increased comorbidities

Score Interpretation & Guidance

RangeStageDescription
0–0Very Low RiskScore 0 points
1–1Low RiskScore 1 point
2–2Moderate RiskScore 2 points
3–3Moderate-High RiskScore 3 points
4–4High RiskScore 4 points
5–12Very High RiskScore 5-12 points

Evidence-Based References (EBM)

  • Spyropoulos AC, Anderson FA Jr, FitzGerald G, et al. Predictive and associative models to identify hospitalized medical patients at risk for VTE. Chest. 2011 Sep;140(3):706-714. doi: 10.1378/chest.10-1944.DOI: 10.1378/chest.10-1944
  • Hostler DC, Marx ES, Moores LK, et al. Validation of the International Medical Prevention Registry on Venous Thromboembolism bleeding risk model. Chest. 2016 Apr;149(4):1002-1009. doi: 10.1378/chest.15-2082.DOI: 10.1378/chest.15-2082
  • Rosenberg D, Eichorn A, Alarcon M, et al. External validation of the risk assessment model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for medical patients in a tertiary health system. J Am Heart Assoc. 2014 Nov 4;3(6):e001152. doi: 10.1161/JAHA.114.001152.DOI: 10.1161/JAHA.114.001152

Related calculators